Olympus joined forces with Revival Healthcare Capital in July to launch Swan EndoSurgical, a new company focused on developing robotic technology that could transform gastrointestinal care.
Here are five things to know about the deal:
1. Swan EndoSurgical aims to create a minimally invasive, endoluminal platform that can navigate the GI tract like an endoscope, but with the added precision of deployable robotic arms, according to a July news release.
2. Tokyo-based Olympus and the Texas-based Revival have committed an initial $65 million to the new company. That figure could rise to as much as $458 million if Swan meets a series of development milestones.
3. Revival will maintain majority control, while Olympus will hold a significant equity stake and contribute its visualization and GI endoscopy expertise.
4. Swan EndoSurgical will be headquartered in Boston, with a technology center based in Cambridge, U.K. The company has already assembled a leadership team of experienced medtech professionals to drive its clinical, technical and commercial strategy.
5. Under the terms of the agreement, Olympus has the option to acquire Swan at a predetermined valuation if the startup achieves its milestones, according to the release. Should Olympus choose not to exercise that option, Revival will retain ownership.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.